Eori Noda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eori Noda has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Masashi Akiyama
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Japan
6 shared publications - Yoshinao Muro
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
6 shared publications - Haruka Koizumi
Department of Dermatology Toyota Memorial Hospital Toyota Aichi Japan
5 shared publications - Mariko Ogawa-Momohara
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
5 shared publications - Norika Akashi
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Japan
5 shared publications Satoshi Kamiya
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Japan
5 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (11) , 1626-1637
Multicenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies
We aimed to measure anti‐nuclear matrix protein 2 antibody (anti‐NXP2) titers in patients with anti‐NXP2‐positive idiopathic inflammatory myopathies, investigate whether these titers are associated with clinical manifestations, malignancy risk, and treatment response, and compare the clinical and serological features between anti‐NXP2‐positive and anti‐transcriptional intermediary factor 1‐γ antibody (anti‐TIF1‐γ)‐positive dermatomyositis in order to identify practical indicators for differentiating the two subsets. We established a newly optimized in‐house enzyme‐linked immunosorbent assay for the quantitative measurement of anti‐NXP2. After excluding two of the 34 initially identified patients with anti‐NXP2 antibody reactivity, we used the assay to analyse sera from 32 patients with anti‐NXP2‐positive idiopathic inflammatory myopathy. Clinical correlations between anti‐NXP2 titers and inflammatory indices, cardiothoracic ratio, malignancy status, and longitudinal changes after immunosuppressive therapy were examined. We developed a novel clinical scoring system to differentiate between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. The anti‐TIF1‐γ‐positive patients showed a higher frequency of classic dermatomyositis skin manifestations, whereas the anti‐NXP2‐positive patients had significantly higher creatine kinase, aldolase, and lactate dehydrogenase levels, indicating more prominent muscle involvement. Anti‐NXP2 titers correlated with erythrocyte sedimentation rate and cardiothoracic ratio and were significantly higher in patients with malignancy in the anti‐NXP2‐positive idiopathic inflammatory myopathy patients. Longitudinal analyses demonstrated declines in antibody titers after immunosuppressive treatment. Our scoring system, incorporating age at onset, Gottron's sign, creatine kinase, lactate dehydrogenase, and malignancy status, highly accurately distinguished between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. Anti‐NXP2 titers reflect systemic inflammation, cardiac involvement, and malignancy risk in anti‐NXP2‐positive idiopathic inflammatory myopathy. The observed decline in anti‐NXP2 titers after therapy suggests the potential utility of these titers as biomarkers for longitudinal disease assessment and stratifying malignancy risk.
- 16 September 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (11) , 1626-1637
Open AccessMulticenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies
We aimed to measure anti‐nuclear matrix protein 2 antibody (anti‐NXP2) titers in patients with anti‐NXP2‐positive idiopathic inflammatory myopathies, investigate whether these titers are associated with clinical manifestations, malignancy risk, and treatment response, and compare the clinical and serological features between anti‐NXP2‐positive and anti‐transcriptional intermediary factor 1‐γ antibody (anti‐TIF1‐γ)‐positive dermatomyositis in order to identify practical indicators for differentiating the two subsets. We established a newly optimized in‐house enzyme‐linked immunosorbent assay for the quantitative measurement of anti‐NXP2. After excluding two of the 34 initially identified patients with anti‐NXP2 antibody reactivity, we used the assay to analyse sera from 32 patients with anti‐NXP2‐positive idiopathic inflammatory myopathy. Clinical correlations between anti‐NXP2 titers and inflammatory indices, cardiothoracic ratio, malignancy status, and longitudinal changes after immunosuppressive therapy were examined. We developed a novel clinical scoring system to differentiate between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. The anti‐TIF1‐γ‐positive patients showed a higher frequency of classic dermatomyositis skin manifestations, whereas the anti‐NXP2‐positive patients had significantly higher creatine kinase, aldolase, and lactate dehydrogenase levels, indicating more prominent muscle involvement. Anti‐NXP2 titers correlated with erythrocyte sedimentation rate and cardiothoracic ratio and were significantly higher in patients with malignancy in the anti‐NXP2‐positive idiopathic inflammatory myopathy patients. Longitudinal analyses demonstrated declines in antibody titers after immunosuppressive treatment. Our scoring system, incorporating age at onset, Gottron's sign, creatine kinase, lactate dehydrogenase, and malignancy status, highly accurately distinguished between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. Anti‐NXP2 titers reflect systemic inflammation, cardiac involvement, and malignancy risk in anti‐NXP2‐positive idiopathic inflammatory myopathy. The observed decline in anti‐NXP2 titers after therapy suggests the potential utility of these titers as biomarkers for longitudinal disease assessment and stratifying malignancy risk.
- 10 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7)
Paraspinal Muscle Atrophy on Chest CT as a Prognostic Marker for Anti‐Aminoacyl‐ tRNA Synthetase Antibody‐Positive Myositis
- 10 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7)
Paraspinal Muscle Atrophy on Chest CT as a Prognostic Marker for Anti‐Aminoacyl‐ tRNA Synthetase Antibody‐Positive Myositis
- 1 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (12)
Anti‐Ki/ SL Antibody‐Positive Deep Morphea Patient Also Positive for Anti‐ PL ‐12 and Anti‐Ro60 Antibodies
- 1 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (12)
Anti‐Ki/ SL Antibody‐Positive Deep Morphea Patient Also Positive for Anti‐ PL ‐12 and Anti‐Ro60 Antibodies
- 5 August 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10)
Immune Checkpoint Inhibitor‐Induced IgA Vasculitis With Abundant IgA Anti‐Endothelial Cell Antibodies
- 5 August 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10)
Immune Checkpoint Inhibitor‐Induced IgA Vasculitis With Abundant IgA Anti‐Endothelial Cell Antibodies